Literature DB >> 34233968

Contrast extravasation and outcome of endovascular therapy in acute ischaemic stroke: a systematic review and meta-analysis.

Tao Xu1, You Wang1, Jinxian Yuan1, Yangmei Chen1, Haiyan Luo2.   

Abstract

OBJECTIVE: Contrast extravasation (CE) after endovascular therapy (EVT) is commonly present in acute ischaemic stroke (AIS) patients. Substantial uncertainties remain about the relationship between CE and the outcomes of EVT in patients with AIS. Therefore, we aimed to evaluate this association.
DESIGN: A systematic review and meta-analysis of published studies were performed. DATA SOURCE: We systematically searched the Medline and Embase databases for relevant clinical studies. The last literature search in databases was performed in June 2020. ELIGIBILITY CRITERIA FOR STUDY SELECTION: We included studies exploring the associations between CE and the outcomes of EVT in patients with AIS undergoing EVT. DATA EXTRACTION AND SYNTHESIS: Two reviewers extracted relevant information and data from each article independently. We pooled ORs with CIs using a random-effects meta-analysis to calculate the associations between CE and outcomes of EVT. The magnitude of heterogeneity between estimates was quantified with the I2 statistic with 95% CIs.
RESULTS: Fifteen observational studies that enrolled 1897 patients were included. Patients with CE had higher risks of poor functional outcome at discharge (2.38, 95% CI 1.45 to 3.89 p=0.001; n=545) and poor functional outcome at 90 days (OR 2.16, 95% CI 1.20 to 3.90; n=1194). We found no association between CE and in-hospital mortality (OR 0.95, 95% CI 0.27 to 3.30; n=376) or 90-day mortality (OR 1.38, 95% CI 0.81 to 2.36; n=697) after EVT. Moreover, CE was associated with higher risks of post-EVT intracranial haemorrhage (ICH) (OR 6.68, 95% CI 3.51 to 12.70; n=1721) and symptomatic ICH (OR 3.26, 95% CI 1.97 to 5.40; n=1092).
CONCLUSIONS: This systematic review and meta-analysis indicates that in patients with AIS undergoing EVT, CE is associated with higher risks of unfavourable functional outcomes and ICH. Thus, we should pay more attention to CE in patients with AIS undergoing EVT. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  interventional radiology; neuroradiology; stroke; stroke medicine

Year:  2021        PMID: 34233968      PMCID: PMC8264910          DOI: 10.1136/bmjopen-2020-044917

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


This study assessed the associations between contrast extravasation (CE) and the clinical outcomes of endovascular therapy (EVT) in patients with acute ischaemic stroke. Dual-energy CT (DECT) was considered to be more effective for early differentiation between CE and haemorrhage than nonenhanced computed tomography; however, of the included studies, only four included studies used DECT, which may reduce its diagnostic accuracy for CE, further weakening our results. Most of the included studies made a strict distinction between CE and intracranial haemorrhage (ICH); thus, the clinical relevance between the coexistence of CE and ICH and the outcomes of EVT remains unclear. Most of the included studies included a limited number of subjects, which reduced the strength of this systematic review and meta-analysis. The location and volume of CE is an important confounding factor affecting the association between CE and EVT outcomes; however, most of the included studies did not report this key information.

Introduction

Over the past several years, clinical studies have confirmed the efficacy and safety of endovascular therapy (EVT) for treating acute ischaemic stroke (AIS) caused by large vessel occlusion (LVO).1 In recent clinical practice, EVT has been a standard therapy for patients with AIS caused by LVO.1 Intravascular injection of iodinated contrast media is commonly administered in EVT. Contrast extravasation (CE) after EVT occurs in some patients with AIS receiving EVT treatment.2 CE is usually assessed by a non-enhanced CT (NECT) scan or dual-energy CT (DECT) immediately after EVT and progressively resolves within 24 hours after EVT.3 4 CE is considered a manifestation of early blood–brain barrier (BBB) disruption after EVT, which has been reported to be predictive of poor outcome in patients undergoing EVT for AIS.3 However, among the studies focusing on the prognosis of patients eligible for EVT with CE, some have indicated that patients with CE had a higher risk for impaired functional outcomes, while others found no association between CE and the outcomes of EVT. Thus, this association remains unclear and has substantial uncertainties. Therefore, we aimed to evaluate the association between CE and the outcomes of EVT in AIS by performing a systematic review and meta-analysis.

Methods

Search strategy

We performed this systematic review and meta-analysis based on the Meta-analysis of Observational Studies in Epidemiology guidelines.5 The Medline and Embase databases were systematically searched using a predefined retrieval strategy (online supplemental table 1 in the online data supplement).

Inclusion criteria

We included a study if it met all of the following inclusion criteria: Exposure and outcome: The study investigated the associations between CE and the outcomes of EVT for the treatment of AIS. Definition of EVT: EVT was considered endovascular interventional therapy using aspiration techniques, stent retrievers or intra-arterial thrombolysis for the treatment of AIS. Definition of CE: CE was detected with NECT immediately after EVT, and follow-up NECT, MRI T2-weighted gradient-recall echo imaging (MRI-GRE) or MRI susceptibility-weighted-imaging (MRI-SWI) were conducted 24 hours after EVT6 7; CE was defined as the presence of high density on NECT immediately after EVT but with no discernible high density on 24-hour follow-up NECT after EVT or no hypointensity on 24-hour follow-up MRI-GRE and MRI-SWI after EVT.6 7 Moreover, CE could also be detected with DECT. For DECT, CE was defined as exhibiting high density on mixed energy (MIX) images and iodine overlay maps but no high density in the corresponding areas on virtual noncontrast-enhanced (VNC) images.3 The differential diagnosis between CE and cerebral haemorrhage based on neuroimaging is available in table 1.
Table 1

The assessment strategies of contrast extravasation and haemorrhage after EVT

Assessment methodsDefinition of CEDefinition of haemorrhageIncluded studies
NECT immediately after EVT and a follow-up NECT, MRI-GRE or MRI-SWI at 24 hours after EVTCE was defined as the presence of high density on NECT immediately after EVT, but with no longer discernible high density on 24 hours follow-up NECT after EVT or with no hyposignal on 24 hours follow-up MRI-GRE and MRI-SWI after EVTHaemorrhage was defined as the presence of high density on NECT immediately after EVT, with high density on 24 hours follow-up NECT after EVT or with hyposignal on 24 hours follow-up MRI-GRE and MRI-SWI after EVTRef4 6 7 12 13 15 17–21
Dual-energy CT immediately after EVTCE was defined as the high density on MIX and IOM, but with no high density of corresponding areas on VNCHaemorrhage was defined as the high density on MIX and VNC, but with no high density of corresponding areas on IOMRef2 3 14 16

CE, contrast extravasation; EVT, endovascular therapy; GRE, T2-weighted gradient-recall echo imaging; IOM, iodine overlay maps; MIX, mixed energy images; NECT, non-enhanced computed tomography; SWI, susceptibility-weighted imaging; VNC, virtual non-contrast-enhanced.

Outcome definitions: The following outcomes were recorded: poor functional outcome at 90 days (defined as a modified Rankin Scale score (mRS) ≥3 at 90 days after EVT), poor functional outcome at discharge (defined as an mRS ≥3 at discharge after EVT), in-hospital mortality, 90-day mortality, intracranial haemorrhage (ICH) and symptomatic ICH (sICH) after EVT. Post-EVT ICH was detected with CT or MRI scans after CE assessment and was defined as any haemorrhagic event, including haemorrhagic infarction, parenchymal haemorrhage or ICH-extracerebral haemorrhage8; sICH was defined as ICH with significant neurological aggravation and an increase in National Institutes of Health Stroke Scale score ≥4 in total. Assessment of outcome: The study provided the adjusted or unadjusted OR and the corresponding 95% CI for the magnitude of the association between CE and each outcome of EVT or provided raw data that could be used to calculate the OR and 95% CI. The assessment strategies of contrast extravasation and haemorrhage after EVT CE, contrast extravasation; EVT, endovascular therapy; GRE, T2-weighted gradient-recall echo imaging; IOM, iodine overlay maps; MIX, mixed energy images; NECT, non-enhanced computed tomography; SWI, susceptibility-weighted imaging; VNC, virtual non-contrast-enhanced. Exclusion criteria: Non-original articles, articles with irrelevant outcomes or insufficient data, or case reports were excluded. A study that did not investigate the associations between CE and the outcomes of EVT was considered to have irrelevant outcomes. One study without any data regarding outcome assessment after EVT was considered to have insufficient data (did not meet the fifth inclusion criterion). Two authors (TX and YW) performed the literature search independently. Moreover, the reference lists of the included articles were also examined to obtain relevant studies. A disagreement about the inclusion of a study was resolved by us via our discussion until a consensus was reached. We performed last literature search in June 2020. In this meta-analysis, if there was a significant sample overlap among multiple studies, we included the study with the largest sample size or longest follow-up time.

Data extraction and qualitative assessment

Two reviewers (TX and JY) independently extracted the following data from each article: first author, publication year, territory, study period and design, methods of EVT, demographics of population, sites of vascular lesions, strategies of EVT, and outcomes of EVT. The ORs with 95% CIs or raw data were extracted to calculate pooled ORs. When a study reported both unadjusted and adjusted ORs, the OR from the most fully adjusted model was extracted. When the effect estimates were not provided directly, the ORs and 95% CIs were calculated based on raw data (extracted raw data are listed in online supplemental table 2 in the online data supplement). We assessed the quality of the included studies according to the Newcastle-Ottawa scale (NOS).9 The full NOS score was 9 stars; if a study awarded ≥8 stars, it was defined as a high-quality study.9

Outcome definitions

The primary outcome of this meta-analysis was poor functional outcome at 90 days after EVT. The secondary outcomes included poor functional outcome at discharge, 90-day mortality, in-hospital mortality, ICH and sICH after EVT.

Statistical analysis

We used pooled OR to evaluate the magnitude of the association between CE and each outcome of EVT. The magnitude of heterogeneity between estimates was quantified with the I2 heterogeneity test statistic. We also estimated 95% CIs to assess the magnitude of heterogeneity between estimates.10 We recognised the potential heterogeneity and varied underlying effect sizes between the included studies; thus, we used a random effects model to pool the estimates. To examine the sources of heterogeneity, we also performed subgroup analyses based on predefined variables (eg, study design, sample size, CE assessment strategy, study quality and adjustments for confounders). We also performed meta-regression analyses to assess the influence of predefined variables on the heterogeneity among studies; Pinteraction from meta-regression analyses was used to assess the sources of heterogeneity. We investigated publication bias visually with funnel plots and statistically with Egger’s tests11 when a pooled estimate included ≥5 studies. STATA V.12.0 (StataCorp) was used for the statistical analyses.

Patient and public involvement

Patients and/or the public were not involved in the design, conduct, reporting, or dissemination plans of this study.

Results

Characteristics and quality assessment of the included studies

The initial literature search provided 5360 unduplicated records. A total of 15 articles published between 2004 and 2020 including 1897 patients met our inclusion criteria and were finally included in this meta-analysis2–4 6 7 12–21 (figure 1). Table 1 demonstrates the CE assessment strategies of the included studies. Of the 15 included studies, 11 conducted NECT immediately after EVT and further conducted follow-up NECT, MRI-GRE or MRI-SWI at 24 hours after EVT to assess whether CE had occurred after EVT4 6 7 12 13 15 17–21; only four studies used DECT immediately after EVT to assess CE after EVT.2 3 14 16 The characteristics of each included study are summarised in table 2. Of the 15 included studies, five were from China[2 3 12–14], five were from South Korea,4 6 19–21 two were from France,17 18 one was from the USA,15 one was from Spain16 and one was from Germany.7 Eleven studies had a retrospective design,2–4 6 7 13 15 17 19–21 and four had a prospective design.12 14 16 18 All studies reported that EVT was used for treating AIS, including stent retrievers, aspiration techniques and intra-arterial thrombolysis. Twelve studies reported information on vascular lesion sites: eight studies included patients with AIS caused by LVO in the anterior cerebral circulation (ACC); three studies included patients with AIS caused by LVO in the ACC or posterior cerebral circulation (PCC); and only one study included patients with AIS caused by LVO in the PCC. Most of the included studies had relatively small sample sizes, which ranged from 56 to 220 subjects. The quality assessment of the included studies is summarised in online supplemental table 3 in the online data supplement, and the median score of the included studies was 7.00 (range: 6–9).
Figure 1

Flow chart of the literature search process.

Table 2

Characteristics of the studies included in the meta-analysis

First author, year of publicationCountryParticipants inclusion periodStudy designPrimary methods of EVTVascular lesion locationAge, year/men, %/No. in cohortOutcomes of EVT
Kim et al4South Korea2012–2019RSR, AT and IAACCNA/54.9%/145ICH and sICH
Chen et al3China2016–2019RSR, AP and IAACC (ICA and MCA)63.1%±11.7/75.9%/166Poor functional outcomes at discharge and at 3 months; mortality at discharge and at 3 months; ICH and sICH
Xu et al12China2014–2018PSRNA69.8%±11.7/58.6%/198ICH
Sun et al2China2016–2018RSRPCA60.9%±10.6/82.4%/108Poor functional outcomes at 3 months
Chen et al13China2015–2016RSRACCNA/54.9%/82Poor functional outcomes at 3 months; ICH and sICH
An et al14China2013–2017PSRACC and PCC61.3%±12.8/72%/180Poor functional outcomes at 3 months; mortality at 3 months; ICH and sICH
Shi et al15USANARSR, AT and IAACCNA/42.9%/210Poor functional outcomes at discharge; mortality at discharge; ICH
Renú et al16Spain2010–2013PSRNANA/47.7%/132Poor functional outcomes at 3 months; ICH
Kim et al6South Korea2007–2014RSR, AT and IAACCNA/50.0%/56Poor functional outcomes at discharge; ICH and sICH
Rouchaud et al17France2009–2011RSRACC and PCC63.0 (31.0–90.0)/58.7%/63Poor functional outcomes at 3 months; mortality at 3 months; ICH
Nikoubashman et al7Germany2010–2013RSR, AT and IAACC71.2%±15.4/52.2%/113Poor functional outcomes at discharge and at 3 months; ICH and sICH
Desilles et al18France2007–2011PSRNA63.0/51.8%/220Poor functional outcomes at 3 months; mortality at 3 months; ICH and sICH
Kim et al19South Korea2007–2010RSR, AT and IAACC and PCC64.9%±14.43/55.9%/68Poor functional outcomes at 3 months; mortality at 3 months; sICH
Jang et al20South Korea1999–2004RIAACC64.7%±11.5/67.0%/94ICH
Yoon et al21South Korea1995–2002RIAACCNA/56.5%/62Poor functional outcomes at 3 months; ICH and sICH

ACC, anterior cerebral circulation; AP, angioplasty; AT, aspiration technique; EVT, endovascular therapy; IA, intra-arterial thrombolysis; ICH, intracranial haemorrhage; NA, not available; P, prospective; PCC, posterior cerebral circulation; R, retrospective; sICH, symptomatic intracranial haemorrhage; SR, stent retriever.

Flow chart of the literature search process. Characteristics of the studies included in the meta-analysis ACC, anterior cerebral circulation; AP, angioplasty; AT, aspiration technique; EVT, endovascular therapy; IA, intra-arterial thrombolysis; ICH, intracranial haemorrhage; NA, not available; P, prospective; PCC, posterior cerebral circulation; R, retrospective; sICH, symptomatic intracranial haemorrhage; SR, stent retriever.

The relationship between CE and the outcomes of EVT after AIS

Regarding the functional outcome after EVT, CE was found to be associated with higher risks of poor functional outcome at discharge (OR 2.38, 95% CI 1.45 to 3.89; p=0.001; 4 studies; n=545) and poor 90-day functional outcome (OR 2.16, 95% CI 1.20 to 3.90; p=0.010; 10 studies; n=1194) (figure 2). However, CE was not related to in-hospital mortality (OR 0.95, 95% CI 0.27 to 3.30; p=0.934; 2 studies; n=376) or 90-day mortality (OR 1.38, 95% CI 0.81 to 2.36; p=0.232; 5 studies; n=697) (figure 3). Furthermore, CE was found to be associated with higher risks for post-EVT ICH (OR 6.68, 95% CI 3.51 to 12.70; p<0.001; 13 studies; n=1721) and sICH (OR 3.26, 95% CI 1.97 to 5.40; p<0.001; 9 studies; n=1092) (figure 4).
Figure 2

Summary of ORs for the relationships between contrast extravasation (CE) and poor functional outcomes at discharge and 90 days. Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was associated with higher risks of poor functional outcome at discharge (heterogeneity test: I2=0.0%, 95% CI 0.00 to 0.83) and poor functional outcome at 90 days (heterogeneity test: I2=73.2%, 95% CI 0.50 to 0.86).

Figure 3

Summary of ORs for the relationships between contrast extravasation (CE) and in-hospital mortality and 90-day mortality. Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was not associated with in-hospital mortality (heterogeneity test: I2=66.0%, 95% CI −0.50 to 0.92) or 90-day mortality (heterogeneity test: I2=25.6%, 95% CI −0.85 to 0.70).

Figure 4

Summary of ORs for the relationships between contrast extravasation (CE) and risks for intracranial haemorrhage (ICH) and symptomatic ICH (sICH). Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was related to higher risks of post-EVT ICH (heterogeneity test: I2=78.8%, 95% CI 0.64 to 0.87) and sICH (heterogeneity test: I2=0.0%, 95% CI −4.30 to 0.67). EVT, endovascular therapy.

Summary of ORs for the relationships between contrast extravasation (CE) and poor functional outcomes at discharge and 90 days. Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was associated with higher risks of poor functional outcome at discharge (heterogeneity test: I2=0.0%, 95% CI 0.00 to 0.83) and poor functional outcome at 90 days (heterogeneity test: I2=73.2%, 95% CI 0.50 to 0.86). Summary of ORs for the relationships between contrast extravasation (CE) and in-hospital mortality and 90-day mortality. Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was not associated with in-hospital mortality (heterogeneity test: I2=66.0%, 95% CI −0.50 to 0.92) or 90-day mortality (heterogeneity test: I2=25.6%, 95% CI −0.85 to 0.70). Summary of ORs for the relationships between contrast extravasation (CE) and risks for intracranial haemorrhage (ICH) and symptomatic ICH (sICH). Each diamond indicates the OR, and the horizontal line indicates the 95% CI. CE was related to higher risks of post-EVT ICH (heterogeneity test: I2=78.8%, 95% CI 0.64 to 0.87) and sICH (heterogeneity test: I2=0.0%, 95% CI −4.30 to 0.67). EVT, endovascular therapy.

Heterogeneity assessment

Heterogeneity assessments of pooled estimates were conducted, and the I2 and 95% CIs are listed in the figure legends. Significant heterogeneity was found in the pooled estimates of poor functional outcome at 90 days (I2=73.2%, 95% CI 0.50 to 0.86) and post-EVT ICH (I2=78.80%, 95% CI 0.64 to 0.87). Omitting each study in turn did not alter the significance of pooled estimates and their heterogeneity estimates. Subgroup analyses were performed to assess the relationship between CE and poor 90-day functional outcome (online supplemental table 4 in the online data supplement) and the association between CE and post-EVT ICH (online supplemental table 5 in the online data supplement). The results with significant heterogeneity remained stable in subgroup analyses that were restricted to predefined variables. Based on meta-regression analyses, we found that varied assessment strategies of CE among the included studies accounted for the main between-study heterogeneity (Pinteraction=0.039) (online supplemental table 4 in the online data supplement).

Publication bias assessment

Asymmetric funnel plots were identified in the pooled estimates (included ≥5 studies) (online supplemental figures 1–4 in the online data supplement). However, Egger’s tests indicated no significant publication bias in the pooled estimates (online supplemental table 6 in the online data supplement).

Discussion

Main findings

We performed a systematic review and meta-analysis of the results provided by the 15 included studies having 1897 subjects with EVT for treating AIS caused by LVO.2–4 6 7 12–21 Our findings based on this meta-analysis indicated that the presence of CE immediately after EVT was related to a higher risk of an unfavourable 90-day functional outcome, indicating that patients with CE after EVT may have a higher risk of poor functional recovery. Moreover, we found that patients with CE had higher risks of experiencing ICH and sICH after EVT.

Implications and strength

The mechanism underlying the clinical relevance of the relationship between CE and the outcomes of EVT remains unclear. The pathophysiology of CE after EVT is considered to involve a disruption of the BBB due to initial ischaemia and reperfusion injury.3 16 In patients with AIS, ischaemic insults can injure vascular endothelial cell junctions and cause damage to the endothelial extracellular matrix, which may promote permeability of the BBB, further allowing for leakage of contrast media into the extravascular space.3 Thus, the degree of CE has been reported to be associated with the severity of BBB disruption. In patients undergoing EVT, a delayed reperfusion time (indicating a prolonged ischaemic time) and hyperperfusion after revascularisation may cause greater injury to the vasculature and BBB, further leading to obvious CE after EVT.16 Moreover, procedure-related vascular lesions due to the frequent use of EVT devices and inappropriate operations during EVT may promote BBB disruption.22 Additionally, extravasated contrast media may exert direct toxic effects on local brain tissue, which might damage the tissue.3 16 Thus, CE is considered to be associated with poor outcomes after EVT and may have prognostic value in predicting the outcomes of EVT. Thus, therapeutic strategies (such as shortening the recanalisation time, gentle delivery of the EVT device, and controlling blood pressure after EVT) that are able to protect and stabilise the BBB in the perioperative period of EVT may improve the clinical outcomes of patients with EVT-related CE.

Limitations

This meta-analysis has several limitations. First, DECT is considered to be more accurate for early differentiation between CE and haemorrhage than NECT. However, of the included studies, only four used DECT,2 3 14 16 which may reduce its diagnostic accuracy for CE, further weakening our results. Second, we also noticed the coexistence of CE and haemorrhage immediately after EVT in patients undergoing EVT in clinical practice. However, most of the included studies made a strict distinction between CE and haemorrhage. Thus, the clinical relevance of the relationship between the coexistence of CE and haemorrhage and the outcomes of EVT remains unclear. Third, most of the included studies had small sample sizes. Fourth, the location and volume of CE are key confounders influencing the relationship between CE and the outcomes of EVT in patients with AIS. Most of the included studies, however, did not provide this key information; only two included studies reported that subarachnoid and cortical CE were associated with an elevated risk of ICH.4 6 The effects of CE location and volume on the relationship between CE and the outcomes of EVT remain unclear.

Conclusions

In summary, in patients undergoing EVT for treating AIS due to LVO, CE was related to elevated risks for unfavourable functional outcomes and ICH events after EVT. Our findings highlight that we should pay careful and increased attention to CE in patients undergoing EVT for treating AIS due to LVO. Future studies exploring the association between CE and the outcomes of EVT should take the location and volume of CE into account, which may influence the outcomes of EVT. In this meta-analysis, most eligible studies had retrospective designs; thus, future high-quality prospective studies are needed to explore the association between CE and the outcomes of EVT.
  22 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

2.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

3.  The cortical contrast accumulation from brain computed tomography after endovascular treatment predicts symptomatic hemorrhage.

Authors:  J M Kim; K Y Park; W J Lee; J S Byun; J K Kim; M S Park; S W Ahn; H W Shin
Journal:  Eur J Neurol       Date:  2015-07-01       Impact factor: 6.089

4.  Contrast Extravasation is Predictive of Poor Clinical Outcomes in Patients Undergoing Endovascular Therapy for Acute Ischemic Stroke in the Anterior Circulation.

Authors:  Zhongyun Chen; Yingbo Zhang; Yingying Su; Yijia Sun; Yanbo He; Hongbo Chen
Journal:  J Stroke Cerebrovasc Dis       Date:  2019-11-11       Impact factor: 2.136

Review 5.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

6.  Contrast Extravasation After Endovascular Treatment in Posterior Circulation Stroke.

Authors:  Yijia Sun; Yingying Su; Zhongyun Chen; Yanbo He; Yingbo Zhang; Hongbo Chen
Journal:  World Neurosurg       Date:  2019-06-26       Impact factor: 2.104

7.  Relevance of blood-brain barrier disruption after endovascular treatment of ischemic stroke: dual-energy computed tomographic study.

Authors:  Arturo Renú; Sergio Amaro; Carlos Laredo; Luis San Román; Laura Llull; Antonio Lopez; Xabier Urra; Jordi Blasco; Laura Oleaga; Ángel Chamorro
Journal:  Stroke       Date:  2015-02-05       Impact factor: 7.914

8.  Early Blood-Brain Barrier Disruption after Mechanical Thrombectomy in Acute Ischemic Stroke.

Authors:  Zhong-Song Shi; Gary R Duckwiler; Reza Jahan; Satoshi Tateshima; Viktor Szeder; Jeffrey L Saver; Doojin Kim; Latisha K Sharma; Paul M Vespa; Noriko Salamon; J Pablo Villablanca; Fernando Viñuela; Lei Feng; Yince Loh; David S Liebeskind
Journal:  J Neuroimaging       Date:  2018-02-27       Impact factor: 2.486

9.  Subarachnoid Contrast Accumulation and Alberta Stroke Program Early Computed Tomography Score Applied to Contrast Accumulation After Thrombectomy as Predictors of Symptomatic Hemorrhage.

Authors:  Hyeongseok Kim; Seung-Jae Lee; Tae-Kyeong Lee; Kyu-On Jung
Journal:  World Neurosurg       Date:  2020-03-26       Impact factor: 2.104

10.  The Heidelberg Bleeding Classification: Classification of Bleeding Events After Ischemic Stroke and Reperfusion Therapy.

Authors:  Rüdiger von Kummer; Joseph P Broderick; Bruce C V Campbell; Andrew Demchuk; Mayank Goyal; Michael D Hill; Kilian M Treurniet; Charles B L M Majoie; Henk A Marquering; Michael V Mazya; Luis San Román; Jeffrey L Saver; Daniel Strbian; William Whiteley; Werner Hacke
Journal:  Stroke       Date:  2015-09-01       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.